At this ACR Convergence 2025 session, immunologist Dusan Bogunovic, PhD, discussed his team’s research into how genetic immune diseases manifest with different phenotypes in different people.
Meeting Management Challenges in axSpA
At this ACR Convergence 2025 session, experts discussed emerging concepts with axial spondyloarthritis, including the most effective MRI specifications for diagnosis, challenges with axial juvenile spondyloarthritis & the many mimics of axSpA.
Management of Challenging Cases in Myositis
Immune mediated inflammatory myopathies represent a heterogenous group of diseases with variable degrees of multisystem involvement, including the skin, joints, lungs, and muscles. The ACR Convergence 2025 session, Management of Challenging Cases in Myositis, featured a case-based approach to highlight this complexity, guiding attendees through the nuances of diagnosis and management of antisynthetase syndrome, immune mediated necrotizing myopathy, and dermatomyositis.
Reflections on B Cells in SLE & Lupus Nephritis
At the Dubois Memorial Lecture presented at ACR Convergence 2025, Shaun Jackson, MD, PhD, discussed the evolving understanding of the role of B cells in SLE.
The Role of FGL-1 in Sjögren Disease
Fibrinogen-like protein-1 (FGL-1) may play a key role in the onset of autoimmunity by suppressing T cell activation in primary Sjögren disease, according to findings from Otsuka et al. Their study, which examined the influence of interorgan communication on disease pathogenesis in mice models and patients with primary Sjögren disease, may help facilitate novel diagnostic or therapeutic strategies targeting immune checkpoint molecules in autoimmune diseases.
Updates on Fibromyalgia & the Quest to Alleviate Pain
ACR Convergence 2025 speakers reviewed new fibromyalgia insights, from the first new drug approval since 2009 to nociplastic pain concepts & cognitive behavioral therapy.
Emerging Treatments in Psoriatic Arthritis
At a scientific session of ACR Convergence 2025, Alexis Ogdie, MD, discussed new and forthcoming treatments for psoriatic arthritis.
Let’s Discuss Part 2: More Insights from the ACR Convergence 2025 Review Course
The Review Course at ACR Convergence 2025 provided a comprehensive update for practitioners. Highlights from the sections on cutaneous manifestations of rheumatic diseases, gout, macrophage activation syndrome and vasculitis.
Gout & Cardiometabolic Co-Morbidities
ACR Convergence 2025 experts explore gout’s deep ties to MetS, insulin resistance and cardiovascular mortality, weighing new data on colchicine, febuxostat and SGLT2 inhibitors.
What’s New in Psoriatic Arthritis?
Dr. David Pisetsky curated the research presented at ACR Convergence 2025 and answers the question “What new research on psoriatic arthritis has the potential to impact patient care or future research?”
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 349
- Next Page »